Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 10/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6979570 | 1.00 | LTA4H (0.47) | LTA4HALKTDP1CHRNA3CHRNB4 | |
| SCHEMBL4322026 | 0.94 | LTA4H (0.56) | LTA4HALK | |
| SCHEMBL14769269 | 0.84 | ALK (0.43) | LTA4HALKCHRNA3CHRNB4CHRNA7 | |
| SCHEMBL85466 | 0.84 | ALK (0.43) | LTA4HALKCHRNA3CHRNB4CHRNA7 | |
| SCHEMBL92405 | 0.83 | PKM (0.44) | ALK | |
| SCHEMBL8439888 | 0.82 | CHRNB2 (0.63) | CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL8439884 | 0.82 | CHRNB2 (0.63) | CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL8303860 | 0.82 | CHRNB4 (0.46) | ALKCHRNA3CHRNB4 | |
| SCHEMBL8439886 | 0.82 | CHRNB2 (0.63) | CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL8440489 | 0.81 | CHRNB2 (0.62) | CHRNA3CHRNB4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1100797-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | Pfizer Limited (GB) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000005232-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER LIMITED (GB) | 2000-02-03 | — | — | WO | disclosed |